Marlborough

Marlborough medical device maker Boston Scientific is reporting a fourth-quarter loss of $615 million, primarily due to an $861-million tax charge to bring foreign earnings to the U.S.

Sunovion Pharmaceuticals of Marlborough said Monday a clinical trial for a treatment for those with Parkinson's disease has brought positive results.

Marlborough drug maker RXi Pharmaceuticals has regained compliance with Nasdaq by having 10 straight days with a closing bid price of the company's stock at $1 per share or higher.

Marlborough medical device maker Boston Scientific announced Wednesday an agreement with Santa Rosa-based Millipede, Inc. to potentially acquire the California firm for $540 million.

Two office buildings in Marlborough, including the U.S. home of ReWalk Robotics, have been sold to Oxford-based Minardi Limited Partnership for more than $13 million as the property management firm extends its reach into the MetroWest region.

Boston Scientific announced Jan. 11 it received regulatory approval for a new treatment for chronic pain without the use of opioids.

About 12 years ago, Mark Federico opened the first Anytime Fitness franchise in Marlborough before deciding to create his own independent business in Boost Fitness.

Marlborough drugmaker RXi Pharmaceuticals is shifting its business strategy to focus on the development of the most potentially lucrative of its three treatment areas.

Boston Scientific announced Thursday it has received regulatory approval for a new treatment for chronic pain without the use of opioids.

A Marlborough maker of medical devices to treat cardiac disorders like atrial fibrillation has expanded its partnership with a Japanese firm to bring the products to Asia-Pacific countries.